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Ataxia with oculomotor apraxia type 1 in
Southern Italy
Late onset and variable phenotype
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Abstract—Ataxia with oculomotor apraxia type 1 (AOA1) is an autosomal recessive disorder characterized by early-onset
cerebellar ataxia, oculomotor apraxia, and peripheral neuropathy. The causative gene (APTX) has been recently identified
in Portuguese and Japanese kindreds. Three patients with AOA1 were identified in an APTX mutation screening on 28
Southern Italian patients with progressive ataxia and peripheral neuropathy. A novel homozygous missense mutation
(H201Q) was found in one patient and a Japanese missense mutation (P206L) in two. AOA1 clinical heterogeneity and
onset later than previously described are shown.
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Ataxia with oculomotor apraxia type 1 (AOA1; MIM
208920) is the most frequent cause of autosomal re-
cessive ataxia in Japan and second to Friedreich
ataxia (FRDA) in Portugal.1 It is a neurodegenera-
tive disorder characterized by early-onset, progres-
sive ataxia, peripheral neuropathy, and later
oculomotor apraxia. The gene responsible for AOA1
(APTX) is organized into seven exons and maps to
chromosome 9q13, spanning 17 kbp of genomic DNA.
The encoded protein, aprataxin, has been involved in
DNA single-strand break repair, as it shares similar-
ity with the amino terminus of the polynucleotide
kinase 3'-phosphatase and the histidine triad (HIT)
proteins.2 To date, several missense, nonsense, and
frameshift mutations have been identified in Europe
and Japan.2-6
We report clinical and molecular findings of three
Southern Italian patients with mutations in the
APTX gene.
Patients and methods. Clinical study. Twenty-eight index
cases were selected among the ataxic patients followed at our
department. The inclusion criteria were sporadic or autosomal
recessive progressive cerebellar ataxia, onset within 35 years,
clinical (decreased or absent ankle reflexes and decreased vibra-
tion sense) or neurophysiologic signs of peripheral neuropathy or
both, and exclusion of GAA expansion or point mutation within
the X25 gene. Mean ! SD age at onset was 15 ! 13 years.
Peripheral neurophysiologic examination was performed at me-
dian and posterior tibial nerves with needle electrodes.
Molecular study. Genomic DNA was extracted from periph-
eral blood samples after informed consent. Primer pairs were de-
signed to screen for the seven coding exons of the APTX gene.
Oligonucleotide primer pairs and PCR conditions are available on
the Neurology Web site at www.neurology.org. PCR products were
analyzed by denaturing high-performance liquid chromatography
(DHPLC). DHPLC was performed on a WAVE Nucleic Acid Frag-
ment Analysis System HSM (Transgenomic, Crewe, UK). Patients
with altered DHPLC elution profile were analyzed by direct se-
quencing. PCR products were purified from agarose gels by the
Qiagen gel extraction kit and directly sequenced on an automated
sequencer (ABI 3100; Applied Biosystems, Foster City, CA) using
the ABI-Prism Big-Dye Terminator Cycle Sequencing Ready Reac-
tion Kit (Applied Biosystems).
Results. Case reports. Patient 1 had disease onset at
age 28 with gait imbalance and tendency to fall (table).
The patient became wheelchair bound at age 34. Routine
chemistry showed slight hypoalbuminemia (3.5 g/dL) and
hypercholesterolemia (281 mg/dL). Peripheral nerve con-
duction studies performed elsewhere showed sensory mo-
tor axonal neuropathy, but quantitative data are not
available. Brain MRI revealed cerebellar atrophy more
marked in the vermis.
The parents of Patient 2 were first cousins. Onset of the
disease was at age 29 with mild dysarthria followed by
progressive gait imbalance at 32 years. At age 38, he
needed support for walking. Fasciculations were observed
at the lower limbs. Serum creatine kinase level was ele-
vated (462 U/L; normal 0 to 190 U/L). Sensory action po-
tentials (SAPs) were undetectable at wrist and internal
malleolus. Motor conduction velocities (MCVs) were
slightly decreased at median (50 m/s in the elbow–wrist
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segment; lower limit 54 m/s) and moderately at posterior
tibial nerves (35 m/s in the popliteal fossa–internal malle-
olus segment; lower limit 52 m/s). Brain MRI revealed
moderate cerebellar atrophy and multiple supratentorial
white matter hyperintensities (figure).
Patient 3 had onset at age 8 with progressive gait im-
balance. Sensory conduction velocity was moderately de-
creased at the median (37 m/s in the digit III–wrist
segment; lower limit 51 m/s) and at the posterior tibial
nerves (30 m/s in popliteal fossa–internal malleolus seg-
ment; lower limit 38 m/s). SAP was slightly reduced at the
wrist (5 "V; lower limit 6 "V) and normal at the internal
malleolus (0.6 "V; lower limit 0.2 "V). MCV was slight
decreased at median (48 m/s) and moderately at posterior
tibial nerves (40 m/s) in the same segments explored in
Patient 2. Sural nerve biopsy confirmed axonal neuropathy
with rare onion bulbs. MRI revealed cerebellar atrophy
more marked in the vermis. IQ score was in the lower
limits (88). Wolff–Parkinson–White–like abnormalities
were found at EKG.
Molecular analysis. We identified a homozygous
C-to-T transition at position 617 (we refer to the number-
ing starting at the first ATG codon of the long mRNA
form), leading to the substitution of proline for leucine at
position 206 of aprataxin (P206L). This mutation is one of
the most frequent in Japan.2,4,7 Sequencing of the APTX
gene in Patient 2 showed a new homozygous missense
mutation 603T3A, which results in the substitution of
histidine for glutamine at amino acid residue 201 (H201Q).
This substitution was not found in 200 Italian control chro-
mosomes. Patient 3 had compound heterozygosity for
P206L and 593C3T, which produces an alanine-to-valine
replacement at residue 198 (A198V). Finally, one patient
carried the substitution 431C3A (S144Y), a polymor-
phism with no detectable effect on the protein.8
Discussion. The relative frequency of AOA1 was
5.7% in a mixed European series of non-FRDA pa-
tients with progressive cerebellar ataxia,5 7.5% in a
Portuguese series of patients with a possible AOA1
phenotype,2 and 11.1% in the current series of pa-
tients with progressive non-FRDA and peripheral
neuropathy.
The most frequent AOA1 phenotype comprises
early-onset (2 to 18 years) cerebellar ataxia with cer-
ebellar atrophy at MRI and areflexia with sensori-
motor axonal neuropathy.4-6 Choreic movements may
be prominent at onset (79%) and decrease in the
course of the disease.5 The typical AOA1 oculomotor
abnormality, frequent but not present in all patients
(86%),5 consists of normal ocular saccade initiation
and increased duration with a succession of multiple
hypometric saccades. Head reaches the target before
the eyes as in congenital oculomotor apraxia, where
initiation of saccades is impaired.9 Thus, eyes–head
lag may be a better definition.
Figure. Patient 2. T1-weighted sagittal MRI showing cer-
ebellar atrophy (A) and T2-weighted axial MRI showing
white matter subcortical hyperintensities (B).
Table Clinical and molecular findings
Finding
Patient no.
1 2 3
Parental consanguinity No Yes No
Sex F M M
Age at onset, y 28 29 8
Age at examination, y 34 45 18
Gait and limb ataxia ### ## #
Dysarthria ## ## #
Nystagmus # # $
Eyes–head lag $ $ #
Tendon reflexes $ $ $
Extensor plantar response $ $ $
Muscle wasting ## ## #
Impaired position/vibration sense # # #
Choreiform movements $ $ #
Scoliosis $ $ #
Pes planus # $ #
Cognitive impairment $ $ #
Aprataxin mutations P206L/P206L H201Q/H201Q P206L/A198V
Presence and severity of features: (#) % mild; (##) % moderate; (###) % severe; ($) % absent.
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Other clinical features include hypoalbuminemia
and hypercholesterolemia in the late stage. Intelli-
gence was normal in the Portuguese series,1 whereas
cognitive impairment was observed in the Japanese.4
Recently, more detailed neuropsychological tests
have shown in the European patients a subcortical
syndrome probably due to disruption of frontocer-
ebellar pathways.5 No immunologic impairment has
been reported. The patients become wheelchair
bound after mean disease duration of 11.2 years.5
Patient 1 is homozygous for P206L, not previously
described in the Caucasian population. P206L is the
second commonest Japanese mutation, and it is con-
stantly associated with hypoalbuminemia, as in Pa-
tient 1, and cognitive impairment, which is absent in
Patient 1. Moreover, the onset (28 years) in this pa-
tient is later than previously described.
Patient 2 is homozygous for the novel H201Q mu-
tation. The same codon is affected in the Japanese
mutation H201R, suggesting a mutational hot spot.
Japanese H201R patients show a typical phenotype
with cognitive impairment.3 Patient 2 shows a
milder clinical presentation with late onset (29
years), no wheelchair use after 16 years of disease
duration, and no cognitive impairment. The less se-
vere presentation in Patient 2 suggests that glu-
tamine substitution at position 201 is less
deleterious than arginine for the protein function.
MRI of this patient showed multiple supratentorial
white matter hyperintensities in the absence of risk
factors for cerebrovascular disease. White matter
changes have not been described previously in AOA1
and may be coincidental. Presence of fasciculations
suggests loss of motor neurons. This may be of inter-
est as mutations in the gene responsible for AOA2,
senataxin, may also cause juvenile ALS.10
Patient 3 is a compound heterozygote for A198V/
P206L. A198V has been identified in a homozygous
state in one Caucasian patient with persistent and
severe chorea.5 Patient 3 had persistence of choreic
movements, suggesting that a single A198V dose is
sufficient to cause this feature.
All the mutations (A198V, H201Q, P206L) are lo-
calized in exon 5 and probably alter the function of
aprataxin, leading to changes in the HIT domain and
in the secondary structure.
Late onset in Patients 1 and 2 and presence of
fasciculations in Patient 2 suggest a wider clinical
presentation and that AOA1 diagnosis should be also
considered in ataxic patients with neuropathy and
onset later than 20 years.
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